Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/olmesartan medoxomil - Autotelic Bio

Next Previous
Drug Profile

Dapagliflozin/olmesartan medoxomil - Autotelic Bio

Alternative Names: ATB-101; ATB-1011/ATB-1012; ATB-1012/ATB-1011

Latest Information Update: 27 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Autotelic Bio
  • Class Antihyperglycaemics; Antihypertensives; Benzhydryl compounds; Chlorobenzenes; Eye disorder therapies; Glucosides; Heart failure therapies; Imidazoles; Obesity therapies; Pyrans; Small molecules; Tetrazoles; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diabetes mellitus; Hypertension

Most Recent Events

  • 17 Oct 2022 Phase-III clinical trials in Diabetes mellitus in South Korea (PO) (NCT05573477)
  • 17 Oct 2022 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT05573477)
  • 12 Oct 2022 Autotelic Bio plans a phase III trial for Essential Hypertension and Type 2 diabetes mellitus in South Korea (PO) in October 2022(NCT05573477)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top